Prenatal treatment of congenital adrenal hyperplasia - Not standard of care

Journal of Genetic Counseling

Volumn 21, Issue 5, 2012, Pages 615-624

  Witchel, Selma Feldman ^a   Miller, Walter L ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ambiguous genitalia; Congenital adrenal hyperplasia; CYP21A2; Ethics; Prenatal dexamethasone; Prenatal treatment

Indexed keywords

CYP21A2 PROTEIN, HUMAN; STEROID 21 MONOOXYGENASE;

ANIMAL; CONGENITAL ADRENAL HYPERPLASIA; ENZYMOLOGY; FEMALE; GENETIC COUNSELING; GENETICS; HUMAN; MALE; MUTATION; PRENATAL DIAGNOSIS; REVIEW;

ADRENAL HYPERPLASIA, CONGENITAL; ANIMALS; FEMALE; GENETIC COUNSELING; HUMANS; MALE; MUTATION; PRENATAL DIAGNOSIS; STEROID 21-HYDROXYLASE;

EID: 84864540527     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-012-9508-8     Document Type: Article

References (96)

1. Asztalos, E. V., Murphy, K. E., Hannah, M. E., Willan, A. R., Matthews, S. G., Ohlsson, A., et al. (2010). Multiple courses of antenatal corticosteroids for preterm birth study: 2-year outcomes. Pediatrics, 126, e1045-e1055.
2. Barker, D. J. P.,Winter, P. D., Osmond, C., Margetts, B., & Simmonds, S. J. (1989). Weight in infancy and death from ischaemic heart disease. Lancet, 2, 577-580.
3. Barker, D. J. P., Bull, A. R., Osmond, C., & Simmonds, S. J. (1990). Fetal and placental size and risk of hypertension in adult life. British Medical Journal, 301, 259-262.
4. Barker, D. J., Hales, C. N., Fall, C. H., Osmond, C., Phipps, K., & Clark, P. M. (1993). Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia, 36, 62-67.
5. Bartha, J. L., Finning, K., & Soothill, P. W. (2003). Fetal sex determination from maternal blood at 6 weeks of gestation when at risk for 21- hydroxylase deficiency. Obstetrics & Gynecology, 101, 1135-1136.
6. Bevilacqua, E., Brunelli, R., & Anceschi, M. M. (2010). Review and meta-analysis: benefits and risks of multiple courses of antenatal corticosteroids. Journal of Maternal Fetal Neonatal Medicine, 23, 244-260.
7. Bidet, M., Bellanné-Chantelot, C., Galand-Portier, M. B., Tardy, V., Billaud, L., Laborde, K., et al. (2009). Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. Journal of Clinical Endocrinology & Metabolism, 94, 1570-1578.
8. Braga, L. H., & Pippi Salle, J. L. (2009). Congenital adrenal hyperplasia: a critical appraisal of the evolution of feminizing genitoplasty and the controversies surrounding gender reassignment. European Journal of Pediatric Surgery, 19, 203-210.
9. Brown, R. W., Diaz, R., Robson, A. C., Kotelevtsev, Y. V., Mullins, J. J., Kaufman, M. H., et al. (1996). The ontogeny of 11 betahydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology, 137, 794-797.
10. Casteràs, A., De Silva, P., Rumsby, G., & Conway, G. S. (2009). Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clinical Endocrinology (Oxf), 70, 833-837.
11. Celsi, G., Kistner, A., Aizman, R., Eklöf, A.-C., Ceccatelli, S., de Santiago, A., et al. (1998). Prenatal dexamethasone causes oligonephria, sodium retention, and higher blood pressure in the offspring. Pediatric Research, 4, 317-322.
12. Coleman, M. A., & Honour, J. W. (2004). Reduced maternal dexamethasone dosage for the prenatal treatment of congenital adrenal hyperplasia. BJOG Int J Obstet Gynecol, 111, 176-178.
13. Concolino, P., Mello, E., Zuppi, C., & Capoluongo, E. (2010).Molecular diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: an update of new CYP21A2 mutations. Clinical Chemistry & Laboratory Medicine, 48, 1057-1062.
14. Crochemore, C., Michaelidis, T. M., Fischer, D., Loeffler, J. P., & Almeida, O. F. (2002). Enhancement of p53 activity and inhibition of neural cell proliferation by glucocorticoid receptor activation. FASEB Journal, 6, 761-770.
15. Crouch, N. S., Liao, L. M., Woodhouse, C. R., Conway, G. S., & Creighton, S. M. (2008). Sexual function and genital sensitivity following feminizing genitoplasty for congenital adrenal hyperplasia. Journal of Urology, 179, 634-638.
16. Czeizel, A. E., & Rockenbauer, M. (1997). Population-based case- control study of teratogenic potential of corticosteroids. Teratology, 56, 335-340.
17. David, M., & Forest, M. G. (1984). Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. Journal of Pediatrics, 105, 799-803.
18. de Vries, A., Holmes, M. C., Heijnis, A., Seier, J. V., Heerden, J., Louw, J., et al. (2007). Prenatal dexamethasone exposure induces changes in nonhuman primate offspring cardiometabolic and hypothalamic-pituitary-adrenal axis function. Journal of Clinical Investigation, 117, 1058-1067.
19. Dickinson, H., Walker, D. W., Wintour, E. M., & Moritz, K. (2007). Maternal dexamethasone treatment at midgestation reduces nephron number and alters renal gene expression in the fetal spiny mouse. American Journal of Physiology; Regulatory Integrative Comparative Physiology, 292, R453-R461.
20. Dumić, M., Brkljacić, L., Speiser, P. W., Wood, E., Crawford, C., Plavsić, V., et al. (1990). An update on the frequency of nonclassic deficiency of adrenal 21-hydroxylase in the Yugoslav population. Acta Endocrinologica (Copenh)., 122, 703-710.
21. Edwards, C. R., Benediktsson, R., Lindsay, R. S., & Seckl, J. R. (1993). Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet, 341, 355-357.
22. Esteban, N. V., Loughlin, T., Yergey, A. L., Zawadzki, J. K., Booth, J. D., Winterer, J. C., et al. (1991). Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. Journal of Clinical Endocrinology & Metabolism, 72, 39-45.
23. Evans, M. I., Chrousos, G. P., Mann, D.W., Larsen, J.W., Jr., Green, I., McCluskey, J., et al. (1985). Pharmacologic suppression of the fetal adrenal gland in utero. Attempted prevention of abnormal external genital masculinization in suspected congenital adrenal hyperplasia. JAMA, 253, 1015-1020.
24. Forest, M. G. (2004). Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Human Reproduction Update, 10, 469-485.
25. Forest, M. G., & Dorr, H. G. (2003). Prenatal therapy in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: retrospective follow-up study of 253 treated pregnancies in 215 families. Endocrinologist, 13, 252-259.
26. Forest, M. G., David, M., & Morel, Y. (1993). Prenatal diagnosis and treatment of 21-hydroxylase deficiency. Journal of Steroid Biochemistry & Molecular Biology, 45, 75-82.
27. Forest, M. G., Morel, Y., & David, M. (1998). Prenatal treatment of congenital adrenal hyperplasia. Trends in Endocrinology & Metabolism, 9, 284-289.
28. Fraser, F. C., & Fainstat, T. D. (1951). Production of congenital defects in the off-spring of pregnant mice treated with cortisone; progress report. Pediatrics, 8, 527-533.
29. Fraser, F. C., & Sajoo, A. (1995). Teratogenic potential of corticosteroids in humans. Teratology, 51, 45-46.
30. Frias, J., Levine, L. S., Oberfield, S. E., Pang, S., Silverstein, J., et al. (2000). Technical report: congenital adrenal hyperplasia. Section on Endocrinology and Committee on Genetics. Pediatrics, 106, 1511-1518.
31. Goldman, A. S., Sharpior, B. H., & Katsumata, M. (1978). Human foetal palatal corticoid receptors and teratogens for cleft palate. Nature, 272, 464-466.
32. Goto, M., Hanley, K. P., Marcos, J., Wood, P. J., Wright, S., Postle, A. D., et al. (2006). In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. Journal of Clinical Investigation, 116, 953-960.
33. Harris, A., & Seckl, J. (2011). Glucocorticoids, prenatal stress and the programming of disease. Hormones & Behavior, 59, 279- 289.
34. Hirvikoski, T., Nordenstrom, A., Lindholm, T., Lindblad, F., Ritzén, E. M., Wedell, A., et al. (2007). Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. Journal of Clinical Endocrinology & Metabolism, 92, 542-548.
35. Hirvikoski, T., Nordenstrom, A., Lindholm, F., Ritzén, E. M., & Lajic, S. (2008). Long-termfollow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems? European Journal of Endocrinology, 159, 309- 316.
36. Hirvikoski, T., Lindholm, T., Lajic, S., & Nordenström, A. (2011). Gender role behaviour in prenatally dexamethasone-treated children at risk for congenital adrenal hyperplasia - a pilot study. Acta Paediatrica, 100 (9), e112-e119. doi:10.1111/j.1651-2227.2011.02260.x.
37. Hirvikoski, T., Nordenstrom, A., Wedell, A., Ritzen, & Lajic, S. (2012). Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: The Swedish experience and stand-point. Journal of Clinical Endocrinology and Metabolism. doi:10.1210/jc.2012-1222.
38. Holmes, M. C., Abrahamsen, C. T., French, K. L., Paterson, J. M., Mullins, J. J., & Seckl, J. R. (2006). The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids. Journal of Neuroscience, 26, 3840-3844.
39. Huang,W. L., Beazley, L. D., Quinlivan, J. A., Evans, S. F., Newnham, J. P., & Dunlop, S. A. (1999). Effect of corticosteroids on brain growth in fetal sheep. Obstetrics & Gynecology, 94, 213-218.
40. Ishimoto, H., & Jaffe, R. B. (2011). Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit. Endocrine Reviews, 32, 317-355.
41. Joint ESPE/LWPES Working Group (Writing Committee: Clayton PE Miller WL, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW) (2002). Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Hormone Research, 58, 188- 195.
42. Joint LWPES/ESPE CAH Working Group (Writing Committee: Clayton PE Miller WL, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW) (2002). Consensus statement on 21-hydroxylase deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Paediatric Endocrinology. Journal of Clinical Endocrinology & Metabolism, 87, 4048- 4953.
43. Kari, M. A., Raivio, K. O., Stenman, U.-H., & Voutilainen, R. (1996). Serum cortisol, dehydroepiandrosterone sulfate, and sterolbinding globulins in preterm neonates: effects of gestational age and dexamethasone therapy. Pediatric Resesarch, 40, 319-324.
44. Kerrigan, J. R., Veldhuis, J. D., Leyo, S. A., Iranmanes, H. A., & Rogol, A. D. (1993). Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. Journal of Clinical Endocrinology & Metabolism, 76, 1505- 1510.
45. Kleinle, S., Lang, R., Fischer, G. F., Vierhapper, H., Waldhauser, F., Födinger, M., et al. (2009). Duplications of the functional CYP21A2 gene are primarily restricted to Q318X alleles: evidence for a founder effect. Journal of Clinical Endocrinology & Metabolism, 94, 3954-3958.
46. Koppens, P. F., Hoogenboezem, T., & Degenhart, H. J. (2002). Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes. Human Genetics, 111, 405-410.
47. Lajic, S.,Wedell, A., Bui, T.-H., Ritzén, E. M.,&Holst, M. (1998). Longterm somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism, 83, 3872-3880.
48. Linder, B. L., Esteban, N. V., Yergey, A. L.,Winterer, J. C., Loriaux, D. L., & Cassorla, F. (1990). Cortisol production rate in childhood and adolescence. Journal of Pediatrics, 117, 892-896.
49. Lindsay, R. S., Lindsay, R. M., Edwards, C. R., & Seckl, J. R. (1996a). Inhibition of 11-beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension, 27, 1200-1204.
50. Lindsay, R. S., Lindsay, R. M., Waddell, B. J., & Seckl, J. R. (1996b). Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia, 39, 1299-1305.
51. Lo, Y. M., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., et al. (1997). Presence of fetal DNA in maternal plasma and serum. Lancet, 350, 485-487.
52. Lo, Y. M., Tein, M. S., Lau, T. K., Haines, C. J., Leung, T. N., Poon, P. M., et al. (1998). Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. American Journal of Human Genetics, 62, 768-775.
53. Mathews, S. G. (2001). Antenatal glucocorticoids and the developing brain: mechanisms of action. Seminars in Neonatology, 6, 309- 317.
54. Mercado, A. B., Wilson, R. C., Cheng, K. C., Wei, J. Q., & New, M. I. (1995). Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Journal of Clinical Endocrinology & Metabolism, 80, 2014-2020.
55. Meyer-Bahlburg, H. F. L., Dolezal, C., Baker, S. W., Carlson, A. D., Obeid, J. S., & New, M. I. (2004). Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. Journal of Clinical Endocrinology & Metabolism, 89, 610-614.
56. Miller, W. L. (1994). Genetics, diagnosis, and management of 21- hydroxylase deficiency. Journal of Clinical Endocrinology & Metabolism, 78, 241-246.
57. Miller, W. L. (1999). Dexamethasone treatment of congenital adrenal hyperplasia - an experimental therapy of unproven safety. Journal of Urology, 162, 537-540.
58. Miller, W. L., & Auchus, R. J. (2011). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews, 32, 81-151.
59. Miller, W. L., & Morel, Y. (1989). Molecular genetics of 21- hydroxylase deficiency. Annual Review of Genetics, 23, 371-393.
60. Moss, T. J., Doherty, D. A., Nitsos, I., Sloboda, D. M., Harding, R., & Newnham, J. P. (2005). Effects into adulthood of single or repeated antenatal corticosteroids in sheep. American Journal of Obstetrics & Gynecology, 192, 146-152.
61. Murphy, K. E., Hannah, M. E., Willan, A. R., Hewson, S. A., Ohlsson, A., Kelly, E. N., et al. (2008). Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet, 372, 2143-2151.
62. Nandagopal, R., Sinaii, N., Avila, N. A., Van Ryzin, C., Chen, W., Finkielstain, G. P., et al. (2011). Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families. European Journal of Endocrinology, 164, 977-984.
63. New, M. I., Carlson, A., Obeid, J., Marshall, I., Cabrera, M. S., Goseco, A., et al. (2001). Extensive personal experience: prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. Journal of Clinical Endocrinology & Metabolism, 86, 5651-5657.
64. Nordenskjöld, A., Holmdahl, G., Frisén, L., Falhammar, H., Filipsson, H., Thorén, M., et al. (2008). Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism, 93, 380-386.
65. Nordenström, A., Frisén, L., Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P. O., et al. (2010). Sexual function and surgical outcome in women with congenital adrenal hyperplasia due to CYP21A2 deficiency: clinical perspective and the patients' perception. Journal of Clinical Endocrinology & Metabolism, 95, 3633-3640.
66. Pang, S., Clark, A. T., Freeman, L. C., Dolan, L. M., Immken, L., Mueller, O. T., et al. (1992). Maternal side-effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism, 75, 249-253.
67. Parajes, S., Quinteiro, C., Domínguez, F., & Loidi, L. (2008). High frequency of copy number variations and sequence variants at CYP21A2 locus: implication for the genetic diagnosis of 21- hydroxylase deficiency. PLoS One, 3(5), e2138.
68. Partsch, C. J., Sippell, W. G., MacKenzie, I. Z., & Aynsley-Green, A. (1991). The steroid hormonal milieu of the undisturbed human fetus and mother at 16-20 weeks gestation. Journal of Clinical Endocrinology & Metabolism, 73, 969-974.
69. Quinlivan, J. A., Dunlop, S. A., Newnham, J. P., Evans, S. F., & Beazley, L. D. (1999). Repeated, but not single, maternal administration of corticosteroids delays myelination in the brain of fetal sheep. Perinat Neonatal Med, 4, 47-55.
70. Reipe, F. G., & Sippell, W. G. (2007). Recent advances in diagnosis, treatment and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Reviews in Endocrine & Metabolic Disorders, 8, 349-363.
71. Reisch, N., Arlt, W., & Krone, N. (2011). Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research in Paediatrics, 76, 73-85.
72. Rijnders, R. J., van der Schoot, C. E., Bossers, B., de Vroede, M. A., & Christiaens, G. C. (2001). Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. Obstetrics & Gynecology, 98, 374-378.
73. Ritzén, E. M. (1998). Prenatal treatment of congenital adrenal hyperplasia: a commentary. Trends in Endocrinology & Metabolism, 9, 293-295.
74. Rivkees, S. A., & Crawford, J. D. (2000). Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Pediatrics, 106, 767-773.
75. Robert, E., Vollset, S. E., Botto, L., Lancaster, P. A. L., Merlob, P., Mastroiacovo, P., et al. (1994). Malformation surveillance and maternal drug exposure: the MADRE project. Risk Safety Med, 6, 78-118.
76. Rodriguez-Pinilla, E., & Martinez-Frias, M. L. (1998). Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology, 58, 2-5.
77. Rowland, J. M., & Hendrickx, A. G. (1983). Corticosteroid teratogenicity. Advances in Veterinary Science & Comparative Medicine, 27, 99-128.
78. Safari, H. R., Fassett, M. J., Souter, I. C., Alsulyman, O. M., & Goodwin, T. M. (1998). The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, doubleblind, controlled study. American Journal of Obstetrics & Gynecology, 179, 921-924.
79. Samarasinghe, R. A., Di Maio, R., Volonte, D., Galbiati, F., Lewis, M., Romero, G., et al. (2011). Nongenomic glucocorticoid receptor action regulates gap junction intercellular communication and neural progenitor cell proliferation. Proceedings National Academy of Science (U S A), 108(40), 16657-16662.
80. Seckl, J. R. (2004). Prenatal glucocorticoids and long-term programming. European Journal of Endocrinology, 151, U49-U62.
81. Seckl, J. R., & Miller, W. L. (1997). How safe is long-term prenatal glucocorticoid treatment? JAMA, 277, 1077-1079.
82. Sloboda, D. M., Challis, J. R. G., Moss, T. J. M., & Newnham, J. P. (2005). Synthetic glucocorticoids: antenatal administration and long-term implications. Current Pharmaceutical Design, 11, 1459-1472.
83. Speiser, P.W., & Miller,W. L. (2008). Prenatal treatment of classic CAH with dexamethasone: pro vs. con. Endocrine News, 33, 15-18.
84. Speiser, P. W., & White, P. C. (2003). Congenital adrenal hyperplasia. New England Journal of Medicine, 349, 776-788.
85. Speiser, P. W., Dupont, B., Rubinstein, P., Piazza, A., Kastelan, A., & New, M. I. (1985). High frequency of nonclassical steroid 21- hydroxylase deficiency. American Journal of Human Genetics, 37, 650-667.
86. Speiser, P. W., New, M. I., Tannin, G. M., Pickering, D., Yang, S. Y., & White, P. C. (1992). Genotype of Yupik Eskimos with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Human Genetics, 88, 647-648.
87. Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., et al. (2010). Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 95, 4133-4160.
88. Styne, D. M., Richards, G. E., Bell, J. J., Conte, F. A., Morishima, A., Kaplan, S. L., et al. (1977). Growth patterns in congenital adrenal hyperplasia - Correlation of glucocorticoid therapy with stature. In P. Lee, L. Plotnick, A. Kowarski, & C. Migeon (Eds.), Congenital adrenal hyperplasia (pp. 247-261). Baltimore: University Park Press.
89. Tajima, T., & Fujieda, K. (2008). Prenatal diagnosis and treatment of steroid 21-hydroxylase deficiency. Clinical Pediatric Endocrinology, 17, 95-102.
90. Therrell, B. L., Jr., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., et al. (1998). Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics, 101, 583-590.
91. Uno, H., Lohmiller, L., Thieme, C., Kemnitz, J.W., Engle,M. J., Roeker, E. B., et al. (1990). Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Developmental Brain Research, 53, 157-167.
92. Wang, X., Zuckerman, B., Pearson, C., Kaufman, G., Chen, C., Wang, G., et al. (2002). Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA, 287, 195-202.
93. White, P. C. (2001). Congenital adrenal hyperplasias. Best Practice & Research. Clinical Endocrinology & Metabolism, 15, 17-41.
94. White, P. C., Mune, T., & Agarwal, A. K. (1997). 11β- hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrine Reviews, 18, 135-156.
95. Wilson, R. C.,Nimkarn, S., Dumić, M.,Obeid, J., Azar,M.R., Najmabadi, H., et al. (2007). Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Molecular Genetics & Metabolism, 90, 414-421.
96. Witchel, S. F., & Azziz, R. (2011). Congenital adrenal hyperplasia. Journal of Pediatric & Adolescent Gynecology, 24(3), 116-126.